Literature DB >> 3922267

Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease.

E Weitzenblum, A Sautegeau, M Ehrhart, M Mammosser, A Pelletier.   

Abstract

Sixteen patients with severe chronic obstructive pulmonary disease (COPD) (average values at the onset of O2 therapy: FEV1, 891 +/- 284 ml; PaO2, 50.2 +/- 6.6 mmHg; PaCO2, 51.0 +/- 6.4 mmHg) underwent 3 consecutive right heart catheterizations. The first was performed 47 +/- 28 months (T0) before the onset of long-term O2 therapy (LTO2). The second was performed just before the onset of LTO2 (T1). The third was performed after 31 +/- 19 months of LTO2 (T2). Oxygen therapy (15 to 18 h/day) was prescribed on the basis of usual criteria. From T0 to T1, PaO2 decreased from 59.3 +/- 9.4 to 50.2 +/- 6.6 mmHg, and mean pulmonary arterial pressure (Ppa) worsened from 23.3 +/- 6.8 to 28.0 +/- 7.4 mmHg (p less than 0.005). From T1 to T2, PaO2 was stable, whereas Ppa decreased from 28.0 +/- 7.4 to 23.9 +/- 6.6 mmHg (p less than 0.05). Pulmonary hypertension improved in 12 of the 16 patients. Before the onset of LTO2 (from T0 to T1), there was a yearly increase in Ppa of 1.47 +/- 2.3 mmHg, whereas during LTO2 a yearly decrease of 2.15 +/- 4.4 mmHg was observed, and the difference between these 2 values was highly significant. The changes in Ppa either from T0 to T1 or from T1 to T2 were not associated with concomitant changes in cardiac output or pulmonary capillary wedge pressure but were related to changes in pulmonary vascular resistance. These results suggest that LTO2 for 15 to 18 h/day can reverse the progression of pulmonary hypertension in a high percentage of patients with severe COPD, but that normalization of Ppa is rarely observed.

Entities:  

Mesh:

Year:  1985        PMID: 3922267     DOI: 10.1164/arrd.1985.131.4.493

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  54 in total

1.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 2.  Chronic cor pulmonale.

Authors:  Emmanuel Weitzenblum
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

Review 3.  The heart in cystic fibrosis.

Authors:  Rowland J Bright-Thomas; A Kevin Webb
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 4.  Should patients have cardiac catheterization prior to long-term oxygen treatment?

Authors:  W MacNee
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 5.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

6.  Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.

Authors:  Raúl San José Estépar; Gregory L Kinney; Jennifer L Black-Shinn; Russell P Bowler; Gordon L Kindlmann; James C Ross; Ron Kikinis; Meilan K Han; Carolyn E Come; Alejandro A Diaz; Michael H Cho; Craig P Hersh; Joyce D Schroeder; John J Reilly; David A Lynch; James D Crapo; J Michael Wells; Mark T Dransfield; John E Hokanson; George R Washko
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

Review 7.  NO: COPD and beyond.

Authors:  A T Jones; T W Evans
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

8.  Long-Term Home Oxygen Therapy: A rational approach.

Authors:  R K Elwood
Journal:  Can Fam Physician       Date:  1992-04       Impact factor: 3.275

Review 9.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

10.  Pulmonary hypertension induced by amosite asbestos: a physiological and morphologic study in the guinea pig.

Authors:  J Wright; B Wiggs; A Churg
Journal:  Lung       Date:  1991       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.